190.95
-5.99 (-3.04%)
| Previous Close | 196.94 |
| Volume | 5,934,275 |
| Price / Sales | 9.04 |
| Price / Book | 15.65 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -4.01 |
| Total Debt/Equity (MRQ) | 6.46% |
| Current Ratio (MRQ) | 13.46 |
| Operating Cash Flow (TTM) | -591.31 M |
| Levered Free Cash Flow (TTM) | -349.13 M |
| Return on Assets (TTM) | -23.09% |
| Return on Equity (TTM) | -36.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Revolution Medicines, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.75 |
|
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 2.02% |
| % Held by Institutions | 105.87% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KELSEY STEPHEN MICHAEL | - | 203.77 | -92,531 | -18,855,042 |
| KIM LORENCE H. | - | 207.32 | -17,090 | -3,543,099 |
| MANCINI ANTHONY | - | 203.35 | -15,448 | -3,141,351 |
| Aggregate Net Quantity | -125,069 | |||
| Aggregate Net Value ($) | -25,539,491 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 204.81 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KELSEY STEPHEN MICHAEL | Officer | 11 Sep 2026 | Automatic sell (-) | 92,531 | 203.77 | 18,855,042 |
| KELSEY STEPHEN MICHAEL | Officer | 11 Sep 2026 | Option execute | 92,531 | - | - |
| MANCINI ANTHONY | Officer | 10 Sep 2026 | Automatic sell (-) | 15,448 | 203.35 | 3,141,351 |
| MANCINI ANTHONY | Officer | 10 Sep 2026 | Option execute | 9,363 | - | - |
| KIM LORENCE H. | Director | 08 Sep 2026 | Automatic sell (-) | 17,090 | 207.32 | 3,543,099 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |